Yingwen Dong

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

Merit Cudkowicz, Leonard H. van den Berg, Jeremy M. Shefner et al. · The Lancet Neurology · 2013 · 235 citations

Medicine, Neurology, Pharmacology +8

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A

Johnny Mahlangu, Margaret V. Ragni, Naresh Gupta et al. · Thrombosis and Haemostasis · 2016 · 47 citations

Medicine, Hematology, Perioperative Medicine +16

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Paolo Andrea Zucali, Chia‐Chi Lin, Bradley Curtis Carthon et al. · Journal for ImmunoTherapy of Cancer · 2022 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Population Pharmacokinetics and Pharmacodynamics of Caspofungin in Pediatric Patients

Chi‐Chung Li, Peng Sun, Yingwen Dong et al. · Antimicrobial Agents and Chemotherapy · 2011 · 37 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics

Stacy A. Rudnicki, James D. Berry, Evan W. Ingersoll et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2012 · 30 citations

Medicine, Neurology, Pharmacotherapy +16